VIVO Overzicht aandelen
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide.
Sneeuwvlok Score | |
---|---|
Waardering | 4/6 |
Toekomstige groei | 0/6 |
Prestaties in het verleden | 1/6 |
Financiële gezondheid | 6/6 |
Dividenden | 0/6 |
Meridian Bioscience, Inc. Concurrenten
Prijsgeschiedenis en prestaties
Historische aandelenkoersen | |
---|---|
Huidige aandelenkoers | US$33.97 |
52 Week Hoogtepunt | US$34.38 |
52 Week Laag | US$21.09 |
Bèta | 0.23 |
11 maand verandering | 2.29% |
3 maanden verandering | 6.02% |
1 Jaar Verandering | 54.34% |
33 jaar verandering | 295.23% |
5 jaar verandering | 128.75% |
Verandering sinds IPO | 6,030.20% |
Recent nieuws en updates
Recent updates
Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M
Aug 05Meridian Bioscience: High-Probability Merger Arbitrage
Jul 26Meridian Bioscience downgraded at William Blair on $1.53B acquisition
Jul 07Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet
Jun 27Meridian Bioscience: Correctly Valued
Jun 26Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital
Jun 09Meridian Bioscience: Deceptively Priced
Mar 14Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns
Feb 03These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely
Jul 19If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy
Jul 08Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine
May 10Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation
May 08Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly
Mar 31Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?
Mar 11Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%
Feb 24Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues
Feb 09Meridian expands production capacity for COVID-19 tests with NIH funding
Feb 03Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?
Jan 27Rendement voor aandeelhouders
VIVO | US Medical Equipment | US Markt | |
---|---|---|---|
7D | 0.06% | 0.3% | -1.9% |
1Y | 54.3% | 25.8% | 30.4% |
Rendement versus industrie: VIVO exceeded the US Medical Equipment industry which returned -3.3% over the past year.
Rendement versus markt: VIVO exceeded the US Market which returned 14.1% over the past year.
Prijsvolatiliteit
VIVO volatility | |
---|---|
VIVO Average Weekly Movement | 2.3% |
Medical Equipment Industry Average Movement | 8.1% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 15.0% |
10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: VIVO has not had significant price volatility in the past 3 months.
Volatiliteit in de loop van de tijd: VIVO's weekly volatility (2%) has been stable over the past year.
Over het bedrijf
Opgericht | Werknemers | CEO | Website |
---|---|---|---|
1976 | 704 | Jack Kenny | www.meridianbioscience.com |
Meridian Bioscience, Inc. Samenvatting
VIVO fundamentele statistieken | |
---|---|
Marktkapitalisatie | US$1.49b |
Inkomsten(TTM) | US$42.46m |
Inkomsten(TTM) | US$333.02m |
35.2x
Koers/Winstverhouding4.5x
P/S-verhoudingIs VIVO overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
VIVO resultatenrekening (TTM) | |
---|---|
Inkomsten | US$333.02m |
Kosten van inkomsten | US$144.66m |
Brutowinst | US$188.36m |
Overige uitgaven | US$145.90m |
Inkomsten | US$42.46m |
Laatst gerapporteerde inkomsten
Sep 30, 2022
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) | 0.96 |
Brutomarge | 56.56% |
Nettowinstmarge | 12.75% |
Schuld/Eigen Vermogen Verhouding | 6.8% |
Hoe presteerde VIVO op de lange termijn?
Bekijk historische prestaties en vergelijking